Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 4, 2024

Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days

GlobeNewswire March 12, 2024

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

GlobeNewswire March 5, 2024

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire February 29, 2024

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

GlobeNewswire February 22, 2024

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024

GlobeNewswire January 8, 2024

Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 4, 2023

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

GlobeNewswire December 2, 2023

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

GlobeNewswire November 29, 2023

Xenon Pharmaceuticals Announces Proposed Public Offering

GlobeNewswire November 29, 2023

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

GlobeNewswire November 27, 2023

Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

GlobeNewswire November 9, 2023

Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2023

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update

GlobeNewswire November 1, 2023

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b "X-TOLE" Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

GlobeNewswire October 9, 2023

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

GlobeNewswire October 6, 2023

Xenon Pharmaceuticals to Present at TD Cowen's 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

GlobeNewswire September 14, 2023

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

GlobeNewswire September 12, 2023

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

GlobeNewswire September 4, 2023